Rossari Biotech Limited has informed the Exchange about Investor Presentation
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech filed its Q1 FY26 earnings presentation. Consolidated revenue grew 11% YoY to Rs. 543.7 crore, driven by HPPC (+16% YoY) and AHN (+11% YoY) segments, while the TSC (Textile Specialty Chemicals) segment declined 8% YoY. EBITDA rose 4.6% to Rs. 67.9 crore, but margins contracted 80 basis points to 12.5%. PAT slipped 3.7% YoY to Rs. 33.6 crore with margins falling to 6.2%. Core businesses ex-Institutional and B2C segments delivered a healthier EBITDA margin of ~16%. Management said capacity expansion projects across verticals are progressing in phases, with commissioning over the coming quarters and expected to drive growth from FY27 onwards.
Mixed quarter for shareholders: topline growth was healthy but margin compression and a decline in PAT could temper sentiment. The long-term capacity expansion story remains intact, but near-term return ratios (ROCE, ROE) have moderated and investors may await FY27 for acceleration.